<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">30096863</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2076-3425</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>8</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Aug</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain sciences</Title>
          <ISOAbbreviation>Brain Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Individualized Immunological Data for Precise Classification of OCD Patients.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">149</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci8080149</ELocationID>
        <Abstract>
          <AbstractText>Obsessive⁻compulsive disorder (OCD) affects about 2% of the general population, for which several etiological factors were identified. Important among these is immunological dysfunction. This review aims to show how immunology can inform specific etiological factors, and how distinguishing between these etiologies is important from a personalized treatment perspective. We found discrepancies concerning cytokines, raising the hypothesis of specific immunological etiological factors. Antibody studies support the existence of a potential autoimmune etiological factor. Infections may also provoke OCD symptoms, and therefore, could be considered as specific etiological factors with specific immunological impairments. Finally, we underline the importance of distinguishing between different etiological factors since some specific treatments already exist in the context of immunological factors for the improvement of classic treatments.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lamothe</LastName>
            <ForeName>Hugues</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France. lamothehugues@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institut du Cerveau et de la Moelle Epinière, Sorbonne Universités, UPMC Univ Paris 06, CNRS, INSERM, 75013 Paris, France. lamothehugues@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fondation FondaMental, 94000 Créteil, France. lamothehugues@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baleyte</LastName>
            <ForeName>Jean-Marc</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France. jean-marc.baleyte@chicreteil.fr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fondation FondaMental, 94000 Créteil, France. jean-marc.baleyte@chicreteil.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Pauline</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institut du Cerveau et de la Moelle Epinière, Sorbonne Universités, UPMC Univ Paris 06, CNRS, INSERM, 75013 Paris, France. pauline.hh.smith@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pelissolo</LastName>
            <ForeName>Antoine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Fondation FondaMental, 94000 Créteil, France. a.pelissolo@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Assistance Publique-Hôpitaux de Paris, Pôle de Psychiatrie, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Université Paris-Est Créteil, 94000 Créteil, France. a.pelissolo@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>INSERM, U955, Team 15, 94000 Créteil, France. a.pelissolo@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mallet</LastName>
            <ForeName>Luc</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institut du Cerveau et de la Moelle Epinière, Sorbonne Universités, UPMC Univ Paris 06, CNRS, INSERM, 75013 Paris, France. luc.mallet@inserm.fr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fondation FondaMental, 94000 Créteil, France. luc.mallet@inserm.fr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Assistance Publique-Hôpitaux de Paris, Pôle de Psychiatrie, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Université Paris-Est Créteil, 94000 Créteil, France. luc.mallet@inserm.fr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Mental Health and Psychiatry, Global Health Institute, University of Geneva, 1202 Geneva, Switzerland. luc.mallet@inserm.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>08</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Brain Sci</MedlineTA>
        <NlmUniqueID>101598646</NlmUniqueID>
        <ISSNLinking>2076-3425</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">OCD</Keyword>
        <Keyword MajorTopicYN="N">Streptococcus pyogenes</Keyword>
        <Keyword MajorTopicYN="N">Tourette syndrome</Keyword>
        <Keyword MajorTopicYN="N">Toxoplasma gondii</Keyword>
        <Keyword MajorTopicYN="N">cytokines</Keyword>
        <Keyword MajorTopicYN="N">immunology</Keyword>
        <Keyword MajorTopicYN="N">obsessive–compulsive disorder</Keyword>
        <Keyword MajorTopicYN="N">pediatric acute-onset neuropsychiatric syndrome (PANS)</Keyword>
        <Keyword MajorTopicYN="N">pediatric autoimmune neuropsychological disorders associated with streptococcal infection (PANDAS)</Keyword>
        <Keyword MajorTopicYN="N">psychiatry</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30096863</ArticleId>
        <ArticleId IdType="pmc">PMC6119917</ArticleId>
        <ArticleId IdType="doi">10.3390/brainsci8080149</ArticleId>
        <ArticleId IdType="pii">brainsci8080149</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pauls D.L., Abramovitch A., Rauch S.L., Geller D.A. Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective. Nat. Rev. Neurosci. 2014;15:410–424. doi: 10.1038/nrn3746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn3746</ArticleId>
            <ArticleId IdType="pubmed">24840803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association. DSM-5 Task Force  . Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. American Psychiatric Association; Washington, DC, USA: 2013. 947p </Citation>
        </Reference>
        <Reference>
          <Citation>Abramowitz J.S., Taylor S., McKay D. Obsessive-compulsive disorder. Lancet. 2009;374:491–499. doi: 10.1016/S0140-6736(09)60240-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)60240-3</ArticleId>
            <ArticleId IdType="pubmed">19665647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotge J.Y., Guehl D., Dilharreguy B., Cuny E., Tignol J., Bioulac B., Allard M., Burbaud P., Aouizerate B. Provocation of obsessive-compulsive symptoms: A quantitative voxel-based meta-analysis of functional neuroimaging studies. J. Psychiatry Neurosci. 2008;33:405–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2527721</ArticleId>
            <ArticleId IdType="pubmed">18787662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haynes W.I., Mallet L. High-frequency stimulation of deep brain structures in obsessive-compulsive disorder: The search for a valid circuit. Eur. J. Neurosci. 2010;32:1118–1127. doi: 10.1111/j.1460-9568.2010.07418.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2010.07418.x</ArticleId>
            <ArticleId IdType="pubmed">21039951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallet L., Polosan M., Jaafari N., Baup N., Welter M.L., Fontaine D., du Montcel S.T., Yelnik J., Chereau I., Arbus C., et al.  Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N. Engl. J. Med. 2008;359:2121–2134. doi: 10.1056/NEJMoa0708514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0708514</ArticleId>
            <ArticleId IdType="pubmed">19005196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burguiere E., Monteiro P., Feng G., Graybiel A.M. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science. 2013;340:1243–1246. doi: 10.1126/science.1232380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1232380</ArticleId>
            <ArticleId IdType="pmc">PMC3876800</ArticleId>
            <ArticleId IdType="pubmed">23744950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costas J., Carrera N., Alonso P., Gurriaran X., Segalas C., Real E., Lopez-Sola C., Mas S., Gasso P., Domenech L., et al.  Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia. Transl. Psychiatry. 2016;6:e768. doi: 10.1038/tp.2016.34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/tp.2016.34</ArticleId>
            <ArticleId IdType="pmc">PMC4872458</ArticleId>
            <ArticleId IdType="pubmed">27023174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappi C., Brentani H., Lima L., Sanders S.J., Zai G., Diniz B.J., Reis V.N., Hounie A.G., Conceicao do Rosario M., Mariani D., et al.  Whole-exome sequencing in obsessive-compulsive disorder identifies rare mutations in immunological and neurodevelopmental pathways. Transl. Psychiatry. 2016;6:e764. doi: 10.1038/tp.2016.30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/tp.2016.30</ArticleId>
            <ArticleId IdType="pmc">PMC4872454</ArticleId>
            <ArticleId IdType="pubmed">27023170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez N., Morer A., Gonzalez-Navarro E.A., Gasso P., Boloc D., Serra-Pages C., Lafuente A., Lazaro L., Mas S. Human-leukocyte antigen class ii genes in early-onset obsessive-compulsive disorder. World J. Biol. Psychiatry. 2017 doi: 10.1080/15622975.2017.1327669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15622975.2017.1327669</ArticleId>
            <ArticleId IdType="pubmed">28562177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frick L., Pittenger C. Microglial dysregulation in OCD, tourette syndrome, and PANDAS. J. Immunol. Res. 2016;2016:8606057. doi: 10.1155/2016/8606057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/8606057</ArticleId>
            <ArticleId IdType="pmc">PMC5174185</ArticleId>
            <ArticleId IdType="pubmed">28053994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dale R.C., Merheb V., Pillai S., Wang D., Cantrill L., Murphy T.K., Ben-Pazi H., Varadkar S., Aumann T.D., Horne M.K., et al.  Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135:3453–3468. doi: 10.1093/brain/aws256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws256</ArticleId>
            <ArticleId IdType="pubmed">23065479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo S.E., Leckman J.F., Rose N.R. From research subgroup to clinical syndrome: Modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome) Pediatr. Ther. 2012;2:1000113. doi: 10.4172/2161-0665.1000113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2161-0665.1000113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutterland A.L., Fond G., Kuin A., Koeter M.W., Lutter R., van Gool T., Yolken R., Szoke A., Leboyer M., de Haan L. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: Systematic review and meta-analysis. Acta Psychiatr. Scand. 2015;132:161–179. doi: 10.1111/acps.12423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/acps.12423</ArticleId>
            <ArticleId IdType="pubmed">25877655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldermann J.C., Schuller T., Huys D., Becker I., Timmermann L., Jessen F., Visser-Vandewalle V., Kuhn J. Deep brain stimulation for tourette-syndrome: A systematic review and meta-analysis. Brain Stimul. 2016;9:296–304. doi: 10.1016/j.brs.2015.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brs.2015.11.005</ArticleId>
            <ArticleId IdType="pubmed">26827109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kisely S., Hall K., Siskind D., Frater J., Olson S., Crompton D. Deep brain stimulation for obsessive-compulsive disorder: A systematic review and meta-analysis. Psychol. Med. 2014;44:3533–3542. doi: 10.1017/S0033291714000981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0033291714000981</ArticleId>
            <ArticleId IdType="pubmed">25066053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blomstedt P., Sjoberg R.L., Hansson M., Bodlund O., Hariz M.I. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurg. 2013;80:e245–e253. doi: 10.1016/j.wneu.2012.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2012.10.006</ArticleId>
            <ArticleId IdType="pubmed">23044000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschtritt M.E., Bloch M.H., Mathews C.A. Obsessive-compulsive disorder: Advances in diagnosis and treatment. JAMA. 2017;317:1358–1367. doi: 10.1001/jama.2017.2200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.2200</ArticleId>
            <ArticleId IdType="pubmed">28384832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 2018;10 doi: 10.1101/cshperspect.a028415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a028415</ArticleId>
            <ArticleId IdType="pmc">PMC5793756</ArticleId>
            <ArticleId IdType="pubmed">28620096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weizman R., Laor N., Barber Y., Hermesh H., Notti I., Djaldetti M., Bessler H. Cytokine production in obsessive-compulsive disorder. Biol. Psychiatry. 1996;40:908–912. doi: 10.1016/0006-3223(95)00520-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-3223(95)00520-X</ArticleId>
            <ArticleId IdType="pubmed">8896778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maes M., Meltzer H.Y., Bosmans E. Psychoimmune investigation in obsessive-compulsive disorder: Assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 β and IL-6 concentrations. Neuropsychobiology. 1994;30:57–60. doi: 10.1159/000119136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000119136</ArticleId>
            <ArticleId IdType="pubmed">7800164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappi C., Muniz R.K., Sampaio A.S., Cordeiro Q., Brentani H., Palacios S.A., Marques A.H., Vallada H., Miguel E.C., Guilherme L., et al.  Association study between functional polymorphisms in the tnf-alpha gene and obsessive-compulsive disorder. Arq. Neuropsiquiatr. 2012;70:87–90. doi: 10.1590/S0004-282X2012000200003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S0004-282X2012000200003</ArticleId>
            <ArticleId IdType="pmc">PMC4479271</ArticleId>
            <ArticleId IdType="pubmed">22311210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontenelle L.F., Barbosa I.G., Luna J.V., de Sousa L.P., Abreu M.N., Teixeira A.L. A cytokine study of adult patients with obsessive-compulsive disorder. Compr. Psychiatry. 2012;53:797–804. doi: 10.1016/j.comppsych.2011.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.comppsych.2011.12.007</ArticleId>
            <ArticleId IdType="pubmed">22300901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fluitman S.B., Denys D.A., Heijnen C.J., Westenberg H.G. Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder. Psychoneuroendocrinology. 2010;35:906–911. doi: 10.1016/j.psyneuen.2009.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psyneuen.2009.12.005</ArticleId>
            <ArticleId IdType="pubmed">20044210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fluitman S., Denys D., Vulink N., Schutters S., Heijnen C., Westenberg H. Lipopolysaccharide-induced cytokine production in obsessive-compulsive disorder and generalized social anxiety disorder. Psychiatry Res. 2010;178:313–316. doi: 10.1016/j.psychres.2009.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2009.05.008</ArticleId>
            <ArticleId IdType="pubmed">20452055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hounie A.G., Cappi C., Cordeiro Q., Sampaio A.S., Moraes I., Rosario M.C., Palacios S.A., Goldberg A.C., Vallada H.P., Machado-Lima A., et al.  Tnf-alpha polymorphisms are associated with obsessive-compulsive disorder. Neurosci. Lett. 2008;442:86–90. doi: 10.1016/j.neulet.2008.07.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2008.07.022</ArticleId>
            <ArticleId IdType="pubmed">18639610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konuk N., Tekin I.O., Ozturk U., Atik L., Atasoy N., Bektas S., Erdogan A. Plasma levels of tumor necrosis factor-α and interleukin-6 in obsessive compulsive disorder. Mediat. Inflamm. 2007;2007:65704. doi: 10.1155/2007/65704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2007/65704</ArticleId>
            <ArticleId IdType="pmc">PMC1847475</ArticleId>
            <ArticleId IdType="pubmed">17497035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denys D., Fluitman S., Kavelaars A., Heijnen C., Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology. 2004;29:945–952. doi: 10.1016/j.psyneuen.2003.08.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psyneuen.2003.08.008</ArticleId>
            <ArticleId IdType="pubmed">15177711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monteleone P., Catapano F., Fabrazzo M., Tortorella A., Maj M. Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiology. 1998;37:182–185. doi: 10.1159/000026500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000026500</ArticleId>
            <ArticleId IdType="pubmed">9648125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brambilla F., Perna G., Bellodi L., Arancio C., Bertani A., Perini G., Carraro C., Gava F. Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol. Psychiatry. 1997;42:976–981. doi: 10.1016/S0006-3223(96)00495-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(96)00495-7</ArticleId>
            <ArticleId IdType="pubmed">9386848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray S.M., Bloch M.H. Systematic review of proinflammatory cytokines in obsessive-compulsive disorder. Curr. Psychiatry Rep. 2012;14:220–228. doi: 10.1007/s11920-012-0272-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11920-012-0272-0</ArticleId>
            <ArticleId IdType="pmc">PMC3625952</ArticleId>
            <ArticleId IdType="pubmed">22477442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colak Sivri R., Bilgic A., Kilinc I. Cytokine, chemokine and bdnf levels in medication-free pediatric patients with obsessive-compulsive disorder. Eur. Child Adolesc. Psychiatry. 2018;27:977–984. doi: 10.1007/s00787-017-1099-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00787-017-1099-3</ArticleId>
            <ArticleId IdType="pubmed">29302747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simsek S., Yuksel T., Cim A., Kaya S. Serum cytokine profiles of children with obsessive-compulsive disorder shows the evidence of autoimmunity. Int. J. Neuropsychopharmacol. 2016;19:pyw027. doi: 10.1093/ijnp/pyw027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ijnp/pyw027</ArticleId>
            <ArticleId IdType="pmc">PMC5006199</ArticleId>
            <ArticleId IdType="pubmed">27207913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao N.P., Venkatasubramanian G., Ravi V., Kalmady S., Cherian A., Yc J.R. Plasma cytokine abnormalities in drug-naive, comorbidity-free obsessive-compulsive disorder. Psychiatry Res. 2015;229:949–952. doi: 10.1016/j.psychres.2015.07.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2015.07.009</ArticleId>
            <ArticleId IdType="pubmed">26187339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez N., Morer A., Gonzalez-Navarro E.A., Serra-Pages C., Boloc D., Torres T., Garcia-Cerro S., Mas S., Gasso P., Lazaro L. Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. J. Neuroinflamm. 2017;14:261. doi: 10.1186/s12974-017-1042-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-017-1042-z</ArticleId>
            <ArticleId IdType="pmc">PMC5746006</ArticleId>
            <ArticleId IdType="pubmed">29284508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C., Ma X., Qi S., Han G., Li Y., Liu Y., Liu L. Association between tnf-alpha-238g/a gene polymorphism and ocd susceptibility: A meta-analysis. Medicine. 2018;97:e9769. doi: 10.1097/MD.0000000000009769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000009769</ArticleId>
            <ArticleId IdType="pmc">PMC5805438</ArticleId>
            <ArticleId IdType="pubmed">29384866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uguz F., Onder Sonmez E., Sahingoz M., Gokmen Z., Basaran M., Gezginc K., Sonmez G., Kaya N., Yilmaz E., Erdem S.S., et al.  Neuroinflammation in the fetus exposed to maternal obsessive-compulsive disorder during pregnancy: A comparative study on cord blood tumor necrosis factor-alpha levels. Compr. Psychiatry. 2014;55:861–865. doi: 10.1016/j.comppsych.2013.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.comppsych.2013.12.018</ArticleId>
            <ArticleId IdType="pubmed">24480417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bo Y., Liu S., Yin Y., Wang Z., Cui J., Zong J., Zhang X., Li X. Association study between IL-1β-511 C/T polymorphism and obsessive-compulsive disorder (OCD) in chinese han population. Int. J. Psychiatry Med. 2013;46:145–152. doi: 10.2190/PM.46.2.b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2190/PM.46.2.b</ArticleId>
            <ArticleId IdType="pubmed">24552038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Yin Y., Liu S., Ma X. A case-control association study between obsessive-compulsive disorder (OCD) and the MCP-1-2518G/A polymorphism in a chinese sample. Rev. Bras. Psiquiatr. 2012;34:451–453. doi: 10.1016/j.rbp.2012.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rbp.2012.01.002</ArticleId>
            <ArticleId IdType="pubmed">23429817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S., Liu Y., Zhang X., Ma X. Lack of association of -251T/A polymorphism in interleukin 8 gene with susceptibility to obsessive-compulsive disorder in Chinese Han population. Cytokine. 2012;59:209–210. doi: 10.1016/j.cyto.2012.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2012.03.021</ArticleId>
            <ArticleId IdType="pubmed">22609211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter L.L., Heninger G.R., McDougle C.J., Tyrka A.R., Epperson C.N., Price L.H. Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Res. 2002;112:257–262. doi: 10.1016/S0165-1781(02)00233-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-1781(02)00233-0</ArticleId>
            <ArticleId IdType="pubmed">12450635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akdis M., Aab A., Altunbulakli C., Azkur K., Costa R.A., Crameri R., Duan S., Eiwegger T., Eljaszewicz A., Ferstl R., et al.  Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 2016;138:984–1010. doi: 10.1016/j.jaci.2016.06.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2016.06.033</ArticleId>
            <ArticleId IdType="pubmed">27577879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuce M., Guner S.N., Karabekiroglu K., Baykal S., Kilic M., Sancak R., Karabekiroglu A. Association of tourette syndrome and obsessive-compulsive disorder with allergic diseases in children and adolescents: A preliminary study. Eur. Rev. Med. Pharmacol. Sci. 2014;18:303–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24563428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial tnf-alpha. Nature. 2006;440:1054–1059. doi: 10.1038/nature04671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature04671</ArticleId>
            <ArticleId IdType="pubmed">16547515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., Beattie M.S., Malenka R.C. Control of synaptic strength by glial tnfalpha. Science. 2002;295:2282–2285. doi: 10.1126/science.1067859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1067859</ArticleId>
            <ArticleId IdType="pubmed">11910117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krabbe G., Minami S.S., Etchegaray J.I., Taneja P., Djukic B., Davalos D., Le D., Lo I., Zhan L., Reichert M.C., et al.  Microglial nfkappab-tnfalpha hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. Proc. Natl. Acad. Sci. USA. 2017;114:5029–5034. doi: 10.1073/pnas.1700477114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1700477114</ArticleId>
            <ArticleId IdType="pmc">PMC5441749</ArticleId>
            <ArticleId IdType="pubmed">28438992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruol D.L. Il-6 regulation of synaptic function in the cns. Neuropharmacology. 2015;96:42–54. doi: 10.1016/j.neuropharm.2014.10.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2014.10.023</ArticleId>
            <ArticleId IdType="pmc">PMC4446251</ArticleId>
            <ArticleId IdType="pubmed">25445486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharyya S., Khanna S., Chakrabarty K., Mahadevan A., Christopher R., Shankar S.K. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology. 2009;34:2489–2496. doi: 10.1038/npp.2009.77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2009.77</ArticleId>
            <ArticleId IdType="pubmed">19675532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morer A., Lazaro L., Sabater L., Massana J., Castro J., Graus F. Antineuronal antibodies in a group of children with obsessive-compulsive disorder and tourette syndrome. J. Psychiatr. Res. 2008;42:64–68. doi: 10.1016/j.jpsychires.2006.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2006.09.010</ArticleId>
            <ArticleId IdType="pubmed">17113107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dale R.C., Heyman I., Giovannoni G., Church A.W. Incidence of anti-brain antibodies in children with obsessive-compulsive disorder. Br. J. Psychiatry. 2005;187:314–319. doi: 10.1192/bjp.187.4.314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.187.4.314</ArticleId>
            <ArticleId IdType="pubmed">16199788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearlman D.M., Vora H.S., Marquis B.G., Najjar S., Dudley L.A. Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: Systematic review and meta-analysis. Br. J. Psychiatry. 2014;205:8–16. doi: 10.1192/bjp.bp.113.137018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.bp.113.137018</ArticleId>
            <ArticleId IdType="pubmed">24986387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaltun I., Kara S.S., Kara T. The relationship between Toxoplasma gondii IgG antibodies and generalized anxiety disorder and obsessive-compulsive disorder in children and adolescents: A new approach. Nord J. Psychiatry. 2018;72:57–62. doi: 10.1080/08039488.2017.1385850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08039488.2017.1385850</ArticleId>
            <ArticleId IdType="pubmed">28990850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mataix-Cols D., Frans E., Perez-Vigil A., Kuja-Halkola R., Gromark C., Isomura K., Fernandez de la Cruz L., Serlachius E., Leckman J.F., Crowley J.J., et al.  A total-population multigenerational family clustering study of autoimmune diseases in obsessive-compulsive disorder and tourette’s/chronic tic disorders. Mol. Psychiatry. 2017 doi: 10.1038/mp.2017.215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2017.215</ArticleId>
            <ArticleId IdType="pmc">PMC5951741</ArticleId>
            <ArticleId IdType="pubmed">29133949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flegr J., Horacek J. Toxoplasma-infected subjects report an obsessive-compulsive disorder diagnosis more often and score higher in obsessive-compulsive inventory. Eur. Psychiatry. 2017;40:82–87. doi: 10.1016/j.eurpsy.2016.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eurpsy.2016.09.001</ArticleId>
            <ArticleId IdType="pubmed">27992837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolini H., Lopez Y., Genis-Mendoza A.D., Manrique V., Lopez-Canovas L., Niubo E., Hernandez L., Bobes M.A., Riveron A.M., Lopez-Casamichana M., et al.  Detection of anti-streptococcal, antienolase, and anti-neural antibodies in subjects with early-onset psychiatric disorders. Actas Esp. Psiquiatr. 2015;43:35–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25812540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer H.S., Mascaro-Blanco A., Alvarez K., Morris-Berry C., Kawikova I., Ben-Pazi H., Thompson C.B., Ali S.F., Kaplan E.L., Cunningham M.W. Neuronal antibody biomarkers for sydenham’s chorea identify a new group of children with chronic recurrent episodic acute exacerbations of tic and obsessive compulsive symptoms following a streptococcal infection. PLoS ONE. 2015;10:e0120499.  doi: 10.1371/journal.pone.0120499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0120499</ArticleId>
            <ArticleId IdType="pmc">PMC4368605</ArticleId>
            <ArticleId IdType="pubmed">25793715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frankovich J., Thienemann M., Pearlstein J., Crable A., Brown K., Chang K. Multidisciplinary clinic dedicated to treating youth with pediatric acute-onset neuropsychiatric syndrome: Presenting characteristics of the first 47 consecutive patients. J. Child Adolesc. Psychopharmacol. 2015;25:38–47. doi: 10.1089/cap.2014.0081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2014.0081</ArticleId>
            <ArticleId IdType="pmc">PMC4340335</ArticleId>
            <ArticleId IdType="pubmed">25695943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox C.J., Zuccolo A.J., Edwards E.V., Mascaro-Blanco A., Alvarez K., Stoner J., Chang K., Cunningham M.W. Antineuronal antibodies in a heterogeneous group of youth and young adults with tics and obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2015;25:76–85. doi: 10.1089/cap.2014.0048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2014.0048</ArticleId>
            <ArticleId IdType="pmc">PMC4340634</ArticleId>
            <ArticleId IdType="pubmed">25658702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebrahimi Taj F., Noorbakhsh S., Ghavidel Darestani S., Shirazi E., Javadinia S. Group a beta-hemolytic streptococcal infection in children and the resultant neuro-psychiatric disorder; A cross sectional study; Tehran, iran. Basic Clin. Neurosci. 2015;6:38–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4741265</ArticleId>
            <ArticleId IdType="pubmed">27504155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Patel P.D., McGuire J.F., Kennel A., Mutch P.J., Parker-Athill E.C., Hanks C.E., Lewin A.B., Storch E.A., Toufexis M.D., et al.  Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotype. J. Child Adolesc. Psychopharmacol. 2015;25:14–25. doi: 10.1089/cap.2014.0062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2014.0062</ArticleId>
            <ArticleId IdType="pmc">PMC4340632</ArticleId>
            <ArticleId IdType="pubmed">25314221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Storch E.A., Lewin A.B., Edge P.J., Goodman W.K. Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Pediatr. 2012;160:314–319. doi: 10.1016/j.jpeds.2011.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2011.07.012</ArticleId>
            <ArticleId IdType="pmc">PMC3227761</ArticleId>
            <ArticleId IdType="pubmed">21868033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leckman J.F., King R.A., Gilbert D.L., Coffey B.J., Singer H.S., Dure L.S.T., Grantz H., Katsovich L., Lin H., Lombroso P.J., et al.  Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: A prospective longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry. 2011;50:108–118.e3. doi: 10.1016/j.jaac.2010.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaac.2010.10.011</ArticleId>
            <ArticleId IdType="pmc">PMC3024577</ArticleId>
            <ArticleId IdType="pubmed">21241948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miman O., Mutlu E.A., Ozcan O., Atambay M., Karlidag R., Unal S. Is there any role of Toxoplasma gondii in the etiology of obsessive-compulsive disorder? Psychiatry Res. 2010;177:263–265. doi: 10.1016/j.psychres.2009.12.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2009.12.013</ArticleId>
            <ArticleId IdType="pubmed">20106536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gause C., Morris C., Vernekar S., Pardo-Villamizar C., Grados M.A., Singer H.S. Antineuronal antibodies in OCD: Comparisons in children with OCD-only, OCD+Chronic tics and OCD+PANDAS. J. Neuroimmunol. 2009;214:118–124. doi: 10.1016/j.jneuroim.2009.06.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.06.015</ArticleId>
            <ArticleId IdType="pubmed">19628285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirvan C.A., Swedo S.E., Snider L.A., Cunningham M.W. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J. Neuroimmunol. 2006;179:173–179. doi: 10.1016/j.jneuroim.2006.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2006.06.017</ArticleId>
            <ArticleId IdType="pubmed">16875742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morer A., Vinas O., Lazaro L., Calvo R., Andres S., Bosch J., Gasto C., Massana J., Castro J. Subtyping obsessive-compulsive disorder: Clinical and immunological findings in child and adult onset. J. Psychiatr. Res. 2006;40:207–213. doi: 10.1016/j.jpsychires.2005.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2005.04.003</ArticleId>
            <ArticleId IdType="pubmed">16019031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer H.S., Hong J.J., Yoon D.Y., Williams P.N. Serum autoantibodies do not differentiate PANDAS and tourette syndrome from controls. Neurology. 2005;65:1701–1707. doi: 10.1212/01.wnl.0000183223.69946.f1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000183223.69946.f1</ArticleId>
            <ArticleId IdType="pubmed">16207842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavone P., Bianchini R., Parano E., Incorpora G., Rizzo R., Mazzone L., Trifiletti R.R. Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection. Pediatr. Neurol. 2004;30:107–110. doi: 10.1016/S0887-8994(03)00413-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0887-8994(03)00413-2</ArticleId>
            <ArticleId IdType="pubmed">14984902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Sajid M., Soto O., Shapira N., Edge P., Yang M., Lewis M.H., Goodman W.K. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. Biol. Psychiatry. 2004;55:61–68. doi: 10.1016/S0006-3223(03)00704-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(03)00704-2</ArticleId>
            <ArticleId IdType="pubmed">14706426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo F., Leckman J.F., Katsovich L., Findley D., Grantz H., Tucker D.M., Lombroso P.J., King R.A., Bessen D.E. Prospective longitudinal study of children with tic disorders and/or obsessive-compulsive disorder: Relationship of symptom exacerbations to newly acquired streptococcal infections. Pediatrics. 2004;113:e578–e585. doi: 10.1542/peds.113.6.e578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.113.6.e578</ArticleId>
            <ArticleId IdType="pubmed">15173540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoff-Germain G., Rodriguez R.S., Torres-Alcantara S., Diaz-Jimenez M.J., Swedo S.E., Rapoport J.L. An immunological marker (D8/17) associated with rheumatic fever as a predictor of childhood psychiatric disorders in a community sample. J. Child Psychol. Psychiatry. 2003;44:782–790. doi: 10.1111/1469-7610.00163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1469-7610.00163</ArticleId>
            <ArticleId IdType="pubmed">12831121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy M.L., Pichichero M.E. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group a streptococcal infection (PANDAS) Arch. Pediatr. Adolesc. Med. 2002;156:356–361. doi: 10.1001/archpedi.156.4.356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpedi.156.4.356</ArticleId>
            <ArticleId IdType="pubmed">11929370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisen J.L., Leonard H.L., Swedo S.E., Price L.H., Zabriskie J.B., Chiang S.Y., Karitani M., Rasmussen S.A. The use of antibody D8/17 to identify b cells in adults with obsessive-compulsive disorder. Psychiatry Res. 2001;104:221–225. doi: 10.1016/S0165-1781(01)00323-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-1781(01)00323-7</ArticleId>
            <ArticleId IdType="pubmed">11728611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Benson N., Zaytoun A., Yang M., Braylan R., Ayoub E., Goodman W.K. Progress toward analysis of D8/17 binding to b cells in children with obsessive compulsive disorder and/or chronic tic disorder. J. Neuroimmunol. 2001;120:146–151. doi: 10.1016/S0165-5728(01)00410-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(01)00410-6</ArticleId>
            <ArticleId IdType="pubmed">11694329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson B.S., Leckman J.F., Tucker D., Scahill L., Staib L., Zhang H., King R., Cohen D.J., Gore J.C., Lombroso P. Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive-compulsive, and attention deficit/hyperactivity disorders. Arch. Gen. Psychiatry. 2000;57:364–372. doi: 10.1001/archpsyc.57.4.364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpsyc.57.4.364</ArticleId>
            <ArticleId IdType="pubmed">10768698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marazziti D., Presta S., Pfanner C., Gemignani A., Rossi A., Sbrana S., Rocchi V., Ambrogi F., Cassano G.B. Immunological alterations in adult obsessive-compulsive disorder. Biol. Psychiatry. 1999;46:810–814. doi: 10.1016/S0006-3223(98)00371-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(98)00371-0</ArticleId>
            <ArticleId IdType="pubmed">10494449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman F., Visvanathan K., Carreno-Manjarrez R., Zabriskie J.B. A flow cytometric assay for d8/17 b cell marker in patients with tourette’s syndrome and obsessive compulsive disorder. J. Immunol. Methods. 1998;219:181–186. doi: 10.1016/S0022-1759(98)00141-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-1759(98)00141-0</ArticleId>
            <ArticleId IdType="pubmed">9831399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna S., Ravi V., Shenoy P.K., Chandramukhi A., Channabasavanna S.M. Viral antibodies in blood in obsessive compulsive disorder. Indian J. Psychiatry. 1997;39:190–195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2967113</ArticleId>
            <ArticleId IdType="pubmed">21584073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna S., Ravi V., Shenoy P.K., Chandramuki A., Channabasavanna S.M. Cerebrospinal fluid viral antibodies in obsessive-compulsive disorder in an indian population. Biol. Psychiatry. 1997;41:883–890. doi: 10.1016/S0006-3223(96)00174-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(96)00174-6</ArticleId>
            <ArticleId IdType="pubmed">9099415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Goodman W.K., Fudge M.W., Williams R.C., Jr., Ayoub E.M., Dalal M., Lewis M.H., Zabriskie J.B. B lymphocyte antigen D8/17: A peripheral marker for childhood-onset obsessive-compulsive disorder and tourette’s syndrome? Am. J. Psychiatry. 1997;154:402–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9054790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo S.E., Leonard H.L., Mittleman B.B., Allen A.J., Rapoport J.L., Dow S.P., Kanter M.E., Chapman F., Zabriskie J. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am. J. Psychiatry. 1997;154:110–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8988969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zabriskie J.B., Lavenchy D., Williams R.C., Jr., Fu S.M., Yeadon C.A., Fotino M., Braun D.G. Rheumatic fever-associated B cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum. 1985;28:1047–1051. doi: 10.1002/art.1780280912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.1780280912</ArticleId>
            <ArticleId IdType="pubmed">3876100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patarroyo M.E., Winchester R.J., Vejerano A., Gibofsky A., Chalem F., Zabriskie J.B., Kunkel H.G. Association of a B-cell alloantigen with susceptibility to rheumatic fever. Nature. 1979;278:173–174. doi: 10.1038/278173a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/278173a0</ArticleId>
            <ArticleId IdType="pubmed">310969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morer A., Vinas O., Lazaro L., Bosch J., Toro J., Castro J. D8/17 monoclonal antibody: An unclear neuropsychiatric marker. Behav. Neurol. 2005;16:1–8. doi: 10.1155/2005/795343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2005/795343</ArticleId>
            <ArticleId IdType="pmc">PMC5478839</ArticleId>
            <ArticleId IdType="pubmed">16082074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atmaca M., Kilic F., Koseoglu F., Ustundag B. Neutrophils are decreased in obsessive-compulsive disorder: Preliminary investigation. Psychiatry Investig. 2011;8:362–365. doi: 10.4306/pi.2011.8.4.362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4306/pi.2011.8.4.362</ArticleId>
            <ArticleId IdType="pmc">PMC3246145</ArticleId>
            <ArticleId IdType="pubmed">22216047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber Y., Toren P., Achiron A., Noy S., Wolmer L., Weizman R., Laor N. T cell subsets in obsessive-compulsive disorder. Neuropsychobiology. 1996;34:63–66. doi: 10.1159/000119293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000119293</ArticleId>
            <ArticleId IdType="pubmed">8904733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denys D., Fluitman S., Kavelaars A., Heijnen C., Westenberg H.G. Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. Psychoneuroendocrinology. 2006;31:355–360. doi: 10.1016/j.psyneuen.2005.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psyneuen.2005.08.016</ArticleId>
            <ArticleId IdType="pubmed">16249058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marazziti D., Mungai F., Masala I., Baroni S., Vivarelli L., Ambrogi F., Catena Dell’Osso M., Consoli G., Massimetti G., Dell’Osso L. Normalisation of immune cell imbalance after pharmacological treatments of patients suffering from obsessive-compulsive disorder. J. Psychopharmacol. 2009;23:567–573. doi: 10.1177/0269881108089605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881108089605</ArticleId>
            <ArticleId IdType="pubmed">18755814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marazziti D., Baroni S., Masala I., Giannaccini G., Mungai F., Di Nasso E., Cassano G.B. Decreased lymphocyte 3h-paroxetine binding in obsessive-compulsive disorder. Neuropsychobiology. 2003;47:128–130. doi: 10.1159/000070580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000070580</ArticleId>
            <ArticleId IdType="pubmed">12759554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marazziti D., Ori M., Nardini M., Rossi A., Nardi I., Cassano G.B. Mrna expression of serotonin receptors of type 2c and 5a in human resting lymphocytes. Neuropsychobiology. 2001;43:123–126. doi: 10.1159/000054878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000054878</ArticleId>
            <ArticleId IdType="pubmed">11287788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocca P., Beoni A.M., Eva C., Ferrero P., Maina G., Bogetto F., Ravizza L. Lymphocyte peripheral benzodiazepine receptor mrna decreases in obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 2000;10:337–340. doi: 10.1016/S0924-977X(00)00091-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0924-977X(00)00091-2</ArticleId>
            <ArticleId IdType="pubmed">10974604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindran A.V., Griffiths J., Merali Z., Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. J. Affect. Disords. 1999;52:1–10. doi: 10.1016/S0165-0327(98)00072-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-0327(98)00072-X</ArticleId>
            <ArticleId IdType="pubmed">10357012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocca P., Ferrero P., Gualerzi A., Zanalda E., Maina G., Bergamasco B., Ravizza L. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr. Scand. 1991;84:537–544. doi: 10.1111/j.1600-0447.1991.tb03190.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0447.1991.tb03190.x</ArticleId>
            <ArticleId IdType="pubmed">1686517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursoiu F., Moleriu L., Lungeanu D., Puschita M. The association between hiv clinical disease severity and psychiatric disorders as seen in western romania. AIDS Care. 2018 doi: 10.1080/09540121.2018.1455959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09540121.2018.1455959</ArticleId>
            <ArticleId IdType="pubmed">29592527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dale R.C., Heyman I., Surtees R.A., Church A.J., Giovannoni G., Goodman R., Neville B.G. Dyskinesias and associated psychiatric disorders following streptococcal infections. Arch. Dis. Child. 2004;89:604–610. doi: 10.1136/adc.2003.031856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/adc.2003.031856</ArticleId>
            <ArticleId IdType="pmc">PMC1719997</ArticleId>
            <ArticleId IdType="pubmed">15210487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giulino L., Gammon P., Sullivan K., Franklin M., Foa E., Maid R., March J.S. Is parental report of upper respiratory infection at the onset of obsessive-compulsive disorder suggestive of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection? J. Child Adolesc. Psychopharmacol. 2002;12:157–164. doi: 10.1089/104454602760219199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/104454602760219199</ArticleId>
            <ArticleId IdType="pubmed">12188984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lougee L., Perlmutter S.J., Nicolson R., Garvey M.A., Swedo S.E. Psychiatric disorders in first-degree relatives of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) J. Am. Acad. Child Adolesc. Psychiatry. 2000;39:1120–1126. doi: 10.1097/00004583-200009000-00011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-200009000-00011</ArticleId>
            <ArticleId IdType="pubmed">10986808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnco C., Kugler B.B., Murphy T.K., Storch E.A. Obsessive-compulsive symptoms in adults with lyme disease. Gen. Hosp. Psychiatry. 2018;51:85–89. doi: 10.1016/j.genhosppsych.2018.01.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.genhosppsych.2018.01.009</ArticleId>
            <ArticleId IdType="pubmed">29408088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stagi S., Lepri G., Rigante D., Matucci Cerinic M., Falcini F. Cross-sectional evaluation of plasma vitamin d levels in a large cohort of italian patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Child Adolesc. Psychopharmacol. 2018;28:124–129. doi: 10.1089/cap.2016.0159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0159</ArticleId>
            <ArticleId IdType="pubmed">29112476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calaprice D., Tona J., Parker-Athill E.C., Murphy T.K. A survey of pediatric acute-onset neuropsychiatric syndrome characteristics and course. J. Child Adolesc. Psychopharmacol. 2017;27:607–618. doi: 10.1089/cap.2016.0105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0105</ArticleId>
            <ArticleId IdType="pubmed">28140619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H.C., Lau C.I., Lin C.C., Chang A., Kao C.H. Group a streptococcal infections are associated with increased risk of pediatric neuropsychiatric disorders: A taiwanese population-based cohort study. J. Clin. Psychiatry. 2016;77:e848–e854. doi: 10.4088/JCP.14m09728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.14m09728</ArticleId>
            <ArticleId IdType="pubmed">27464318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Storch E.A., Turner A., Reid J.M., Tan J., Lewin A.B. Maternal history of autoimmune disease in children presenting with tics and/or obsessive-compulsive disorder. J. Neuroimmunol. 2010;229:243–247. doi: 10.1016/j.jneuroim.2010.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2010.08.017</ArticleId>
            <ArticleId IdType="pmc">PMC2991439</ArticleId>
            <ArticleId IdType="pubmed">20864184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurlan R., Johnson D., Kaplan E.L., Tourette Syndrome Study Group  Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: A prospective blinded cohort study. Pediatrics. 2008;121:1188–1197. doi: 10.1542/peds.2007-2657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2007-2657</ArticleId>
            <ArticleId IdType="pubmed">18519489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giedd J.N., Rapoport J.L., Garvey M.A., Perlmutter S., Swedo S.E. Mri assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection. Am. J. Psychiatry. 2000;157:281–283. doi: 10.1176/appi.ajp.157.2.281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ajp.157.2.281</ArticleId>
            <ArticleId IdType="pubmed">10671403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo S.E., Leonard H.L., Garvey M., Mittleman B., Allen A.J., Perlmutter S., Lougee L., Dow S., Zamkoff J., Dubbert B.K. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. Am. J. Psychiatry. 1998;155:264–271. doi: 10.1176/foc.2.3.496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/foc.2.3.496</ArticleId>
            <ArticleId IdType="pubmed">9464208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferretti J.J., Stevens D.L., Fischetti V.A., editors. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA: 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Cunningham M.W.  Post-streptococcal autoimmune sequelae: Rheumatic fever and beyond. In: Ferretti J.J., Stevens D.L., Fischetti V.A., editors. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA: 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Dajani A.S. Guidelines for the diagnosis of rheumatic fever. Jones criteria, 1992 update. Special writing group of the committee on rheumatic fever, endocarditis, and kawasaki disease of the council on cardiovascular disease in the young of the american heart association. JAMA. 1992;268:2069–2073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1404745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanagawa B., Butany J., Verma S. Update on rheumatic heart disease. Curr. Opin. Cardiol. 2016;31:162–168. doi: 10.1097/HCO.0000000000000269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/HCO.0000000000000269</ArticleId>
            <ArticleId IdType="pubmed">26731292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macerollo A., Martino D. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): An evolving concept. Tremor Other Hyperkinet. Mov. 2013;3 doi: 10.7916/D8ZC81M1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7916/D8ZC81M1</ArticleId>
            <ArticleId IdType="pmc">PMC3783973</ArticleId>
            <ArticleId IdType="pubmed">24106651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham M.W., Cox C.J. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: A review of sydenham chorea and beyond. Acta Physiol. 2016;216:90–100. doi: 10.1111/apha.12614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apha.12614</ArticleId>
            <ArticleId IdType="pmc">PMC5812018</ArticleId>
            <ArticleId IdType="pubmed">26454143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J. Movement disorders following cerebrovascular lesion in the basal ganglia circuit. J. Mov. Disords. 2016;9:71–79. doi: 10.14802/jmd.16005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14802/jmd.16005</ArticleId>
            <ArticleId IdType="pmc">PMC4886205</ArticleId>
            <ArticleId IdType="pubmed">27240808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orefici G., Cardona F., Cox C.J., Cunningham M.W.  Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) In: Ferretti J.J., Stevens D.L., Fischetti V.A., editors. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA: 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Cox C.J., Sharma M., Leckman J.F., Zuccolo J., Zuccolo A., Kovoor A., Swedo S.E., Cunningham M.W. Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine d2 receptor: Implications in human disease. J. Immunol. 2013;191:5524–5541. doi: 10.4049/jimmunol.1102592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1102592</ArticleId>
            <ArticleId IdType="pmc">PMC3848617</ArticleId>
            <ArticleId IdType="pubmed">24184556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fibbe L.A., Cath D.C., van den Heuvel O.A., Veltman D.J., Tijssen M.A., van Balkom A.J. Relationship between movement disorders and obsessive-compulsive disorder: Beyond the obsessive-compulsive-tic phenotype. A systematic review. J. Neurol. Neurosurg. Psychiatry. 2012;83:646–654. doi: 10.1136/jnnp-2011-301752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-301752</ArticleId>
            <ArticleId IdType="pubmed">22448031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frick L.R., Rapanelli M., Jindachomthong K., Grant P., Leckman J.F., Swedo S., Williams K., Pittenger C. Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum. Brain. Behav. Immun. 2018;69:304–311. doi: 10.1016/j.bbi.2017.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2017.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC5857467</ArticleId>
            <ArticleId IdType="pubmed">29233751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaspers-Fayer F., Han S.H.J., Chan E., McKenney K., Simpson A., Boyle A., Ellwyn R., Stewart S.E. Prevalence of acute-onset subtypes in pediatric obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2017;27:332–341. doi: 10.1089/cap.2016.0031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0031</ArticleId>
            <ArticleId IdType="pubmed">28121463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leon J., Hommer R., Grant P., Farmer C., D’Souza P., Kessler R., Williams K., Leckman J.F., Swedo S. Longitudinal outcomes of children with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) Eur. Child Adolesc. Psychiatry. 2018;27:637–643. doi: 10.1007/s00787-017-1077-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00787-017-1077-9</ArticleId>
            <ArticleId IdType="pubmed">29119300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skoog G., Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry. 1999;56:121–127. doi: 10.1001/archpsyc.56.2.121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpsyc.56.2.121</ArticleId>
            <ArticleId IdType="pubmed">10025435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calaprice D., Tona J., Murphy T.K. Treatment of pediatric acute-onset neuropsychiatric disorder in a large survey population. J. Child Adolesc. Psychopharmacol. 2018;28:92–103. doi: 10.1089/cap.2017.0101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2017.0101</ArticleId>
            <ArticleId IdType="pmc">PMC5826468</ArticleId>
            <ArticleId IdType="pubmed">28832181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown K., Farmer C., Farhadian B., Hernandez J., Thienemann M., Frankovich J. Pediatric acute-onset neuropsychiatric syndrome response to oral corticosteroid bursts: An observational study of patients in an academic community-based PANS clinic. J. Child Adolesc. Psychopharmacol. 2017;27:629–639. doi: 10.1089/cap.2016.0139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0139</ArticleId>
            <ArticleId IdType="pmc">PMC5749576</ArticleId>
            <ArticleId IdType="pubmed">28714753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spartz E.J., Freeman G.M., Jr., Brown K., Farhadian B., Thienemann M., Frankovich J. Course of neuropsychiatric symptoms after introduction and removal of nonsteroidal anti-inflammatory drugs: A pediatric observational study. J. Child Adolesc. Psychopharmacol. 2017;27:652–659. doi: 10.1089/cap.2016.0179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0179</ArticleId>
            <ArticleId IdType="pubmed">28696783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Brennan E.M., Johnco C., Parker-Athill E.C., Miladinovic B., Storch E.A., Lewin A.B. A double-blind randomized placebo-controlled pilot study of azithromycin in youth with acute-onset obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2017;27:640–651. doi: 10.1089/cap.2016.0190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0190</ArticleId>
            <ArticleId IdType="pubmed">28358599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams K.A., Swedo S.E., Farmer C.A., Grantz H., Grant P.J., D’Souza P., Hommer R., Katsovich L., King R.A., Leckman J.F. Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Am. Acad. Child Adolesc. Psychiatry. 2016;55:860–867.e2. doi: 10.1016/j.jaac.2016.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaac.2016.06.017</ArticleId>
            <ArticleId IdType="pubmed">27663941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigra S., Hesselmark E., Bejerot S. Treatment of PANDAS and PANS: A systematic review. Neurosci. Biobehav. Rev. 2018;86:51–65. doi: 10.1016/j.neubiorev.2018.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2018.01.001</ArticleId>
            <ArticleId IdType="pubmed">29309797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown K.D., Farmer C., Freeman G.M., Jr., Spartz E.J., Farhadian B., Thienemann M., Frankovich J. Effect of early and prophylactic nonsteroidal anti-inflammatory drugs on flare duration in pediatric acute-onset neuropsychiatric syndrome: An observational study of patients followed by an academic community-based pediatric acute-onset neuropsychiatric syndrome clinic. J. Child Adolesc. Psychopharmacol. 2017;27:619–628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5749580</ArticleId>
            <ArticleId IdType="pubmed">28696786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nadeau J.M., Jordan C., Selles R.R., Wu M.S., King M.A., Patel P.D., Hanks C.E., Arnold E.B., Lewin A.B., Murphy T.K., et al.  A pilot trial of cognitive-behavioral therapy augmentation of antibiotic treatment in youth with pediatric acute-onset neuropsychiatric syndrome-related obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2015;25:337–343. doi: 10.1089/cap.2014.0149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2014.0149</ArticleId>
            <ArticleId IdType="pmc">PMC4442557</ArticleId>
            <ArticleId IdType="pubmed">25978743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latimer M.E., L’Etoile N., Seidlitz J., Swedo S.E. Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Child Adolesc. Psychopharmacol. 2015;25:70–75. doi: 10.1089/cap.2014.0080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2014.0080</ArticleId>
            <ArticleId IdType="pmc">PMC4340509</ArticleId>
            <ArticleId IdType="pubmed">25658452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demesh D., Virbalas J.M., Bent J.P. The role of tonsillectomy in the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) JAMA Otolaryngol. Head Neck Surg. 2015;141:272–275. doi: 10.1001/jamaoto.2014.3407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoto.2014.3407</ArticleId>
            <ArticleId IdType="pubmed">25569020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavone P., Rapisarda V., Serra A., Nicita F., Spalice A., Parano E., Rizzo R., Maiolino L., Di Mauro P., Vitaliti G., et al.  Pediatric autoimmune neuropsychiatric disorder associated with group a streptococcal infection: The role of surgical treatment. Int. J. Immunopathol. Pharmacol. 2014;27:371–378. doi: 10.1177/039463201402700307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/039463201402700307</ArticleId>
            <ArticleId IdType="pubmed">25280028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein G.A., Victor A.M., Pipal A.J., Williams K.A. Comparison of clinical characteristics of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and childhood obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2010;20:333–340. doi: 10.1089/cap.2010.0034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2010.0034</ArticleId>
            <ArticleId IdType="pmc">PMC3678581</ArticleId>
            <ArticleId IdType="pubmed">20807071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storch E.A., Murphy T.K., Geffken G.R., Mann G., Adkins J., Merlo L.J., Duke D., Munson M., Swaine Z., Goodman W.K. Cognitive-behavioral therapy for PANDAS-related obsessive-compulsive disorder: Findings from a preliminary waitlist controlled open trial. J. Am. Acad. Child Adolesc. Psychiatry. 2006;45:1171–1178. doi: 10.1097/01.chi.0000231973.43966.a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.chi.0000231973.43966.a0</ArticleId>
            <ArticleId IdType="pubmed">17003662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snider L.A., Lougee L., Slattery M., Grant P., Swedo S.E. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol. Psychiatry. 2005;57:788–792. doi: 10.1016/j.biopsych.2004.12.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopsych.2004.12.035</ArticleId>
            <ArticleId IdType="pubmed">15820236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garvey M.A., Perlmutter S.J., Allen A.J., Hamburger S., Lougee L., Leonard H.L., Witowski M.E., Dubbert B., Swedo S.E. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol. Psychiatry. 1999;45:1564–1571. doi: 10.1016/S0006-3223(99)00020-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(99)00020-7</ArticleId>
            <ArticleId IdType="pubmed">10376116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalbafan M., Mohammadinejad P., Shariat S.V., Alavi K., Zeinoddini A., Salehi M., Askari N., Akhondzadeh S. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2015;48:136–140. doi: 10.1055/s-0035-1549929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0035-1549929</ArticleId>
            <ArticleId IdType="pubmed">25959196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sayyah M., Boostani H., Pakseresht S., Malayeri A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res. 2011;189:403–406. doi: 10.1016/j.psychres.2011.01.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2011.01.019</ArticleId>
            <ArticleId IdType="pubmed">21329988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esalatmanesh S., Abrishami Z., Zeinoddini A., Rahiminejad F., Sadeghi M., Najarzadegan M.R., Shalbafan M.R., Akhondzadeh S. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry Clin. Neurosci. 2016;70:517–526. doi: 10.1111/pcn.12430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pcn.12430</ArticleId>
            <ArticleId IdType="pubmed">27488081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez C.I., Bender J., Jr., Marcus S.M., Snape M., Rynn M., Simpson H.B. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: An open-label trial. J. Clin. Psychiatry. 2010;71:1247–1249. doi: 10.4088/JCP.09l05805blu.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.09l05805blu</ArticleId>
            <ArticleId IdType="pmc">PMC3923525</ArticleId>
            <ArticleId IdType="pubmed">20923629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghanizadeh A., Mohammadi M.R., Bahraini S., Keshavarzi Z., Firoozabadi A., Alavi Shoshtari A. Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: A multicenter randomized double blind placebo controlled clinical trial. Iran. J. Psychiatry. 2017;12:134–141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5483239</ArticleId>
            <ArticleId IdType="pubmed">28659986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa D.L.C., Diniz J.B., Requena G., Joaquim M.A., Pittenger C., Bloch M.H., Miguel E.C., Shavitt R.G. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry. 2017;78:e766–e773. doi: 10.4088/JCP.16m11101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.16m11101</ArticleId>
            <ArticleId IdType="pubmed">28617566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paydary K., Akamaloo A., Ahmadipour A., Pishgar F., Emamzadehfard S., Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled trial. J. Clin. Pharm. Ther. 2016;41:214–219. doi: 10.1111/jcpt.12370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcpt.12370</ArticleId>
            <ArticleId IdType="pubmed">26931055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarris J., Oliver G., Camfield D.A., Dean O.M., Dowling N., Smith D.J., Murphy J., Menon R., Berk M., Blair-West S., et al.  N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29:801–809. doi: 10.1007/s40263-015-0272-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-015-0272-9</ArticleId>
            <ArticleId IdType="pubmed">26374743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Afshar H., Roohafza H., Mohammad-Beigi H., Haghighi M., Jahangard L., Shokouh P., Sadeghi M., Hafezian H. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Clin. Psychopharmacol. 2012;32:797–803. doi: 10.1097/JCP.0b013e318272677d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0b013e318272677d</ArticleId>
            <ArticleId IdType="pubmed">23131885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamdani N., Daban-Huard C., Lajnef M., Richard J.R., Delavest M., Godin O., Le Guen E., Vederine F.E., Lepine J.P., Jamain S., et al.  Relationship between Toxoplasma gondii infection and bipolar disorder in a french sample. J. Affect. Disord. 2013;148:444–448. doi: 10.1016/j.jad.2012.11.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jad.2012.11.034</ArticleId>
            <ArticleId IdType="pubmed">23273549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fond G., Capdevielle D., Macgregor A., Attal J., Larue A., Brittner M., Ducasse D., Boulenger J.P. Toxoplasma gondii: A potential role in the genesis of psychiatric disorders. Encephale. 2013;39:38–43. doi: 10.1016/j.encep.2012.06.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.encep.2012.06.014</ArticleId>
            <ArticleId IdType="pubmed">23095600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strittmatter C., Lang W., Wiestler O.D., Kleihues P. The changing pattern of human immunodeficiency virus-associated cerebral toxoplasmosis: A study of 46 postmortem cases. Acta Neuropathol. 1992;83:475–481. doi: 10.1007/BF00310023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00310023</ArticleId>
            <ArticleId IdType="pubmed">1621505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueno N., Lodoen M.B. From the blood to the brain: Avenues of eukaryotic pathogen dissemination to the central nervous system. Curr. Opin. Microbiol. 2015;26:53–59. doi: 10.1016/j.mib.2015.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mib.2015.05.006</ArticleId>
            <ArticleId IdType="pubmed">26048316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courret N., Darche S., Sonigo P., Milon G., Buzoni-Gatel D., Tardieux I. CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood. 2006;107:309–316. doi: 10.1182/blood-2005-02-0666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2005-02-0666</ArticleId>
            <ArticleId IdType="pmc">PMC1895351</ArticleId>
            <ArticleId IdType="pubmed">16051744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dellacasa-Lindberg I., Fuks J.M., Arrighi R.B., Lambert H., Wallin R.P., Chambers B.J., Barragan A. Migratory activation of primary cortical microglia upon infection with Toxoplasma gondii. Infect. Immun. 2011;79:3046–3052. doi: 10.1128/IAI.01042-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01042-10</ArticleId>
            <ArticleId IdType="pmc">PMC3147544</ArticleId>
            <ArticleId IdType="pubmed">21628522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Notarangelo F.M., Wilson E.H., Horning K.J., Thomas M.A., Harris T.H., Fang Q., Hunter C.A., Schwarcz R. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: Implications for schizophrenia. Schizophr. Res. 2014;152:261–267. doi: 10.1016/j.schres.2013.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.schres.2013.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC3922412</ArticleId>
            <ArticleId IdType="pubmed">24345671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosienko V., Beis D., Pasqualetti M., Waider J., Matthes S., Qadri F., Bader M., Alenina N. Life without brain serotonin: Reevaluation of serotonin function with mice deficient in brain serotonin synthesis. Behav. Brain Res. 2015;277:78–88. doi: 10.1016/j.bbr.2014.06.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2014.06.005</ArticleId>
            <ArticleId IdType="pubmed">24928769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandi Y., Vecsei L. The kynurenine system and immunoregulation. J. Neural. Transm. 2012;119:197–209. doi: 10.1007/s00702-011-0681-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-011-0681-y</ArticleId>
            <ArticleId IdType="pubmed">21744051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadav M.C., Burudi E.M., Alirezaei M., Flynn C.C., Watry D.D., Lanigan C.M., Fox H.S. IFN-gamma-induced ido and wrs expression in microglia is differentially regulated by IL-4. Glia. 2007;55:1385–1396. doi: 10.1002/glia.20544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20544</ArticleId>
            <ArticleId IdType="pmc">PMC2486430</ArticleId>
            <ArticleId IdType="pubmed">17661345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49:15–23. doi: 10.1002/glia.20090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20090</ArticleId>
            <ArticleId IdType="pubmed">15390107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daubener W., MacKenzie C.R. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv. Exp. Med. Biol. 1999;467:517–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10721095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Booij L., Van der Does W., Benkelfat C., Bremner J.D., Cowen P.J., Fava M., Gillin C., Leyton M., Moore P., Smith K.A., et al.  Predictors of mood response to acute tryptophan depletion: A reanalysis. Neuropsychopharmacology. 2002;27:852–861. doi: 10.1016/S0893-133X(02)00361-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0893-133X(02)00361-5</ArticleId>
            <ArticleId IdType="pubmed">12431859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romanelli R.J., Wu F.M., Gamba R., Mojtabai R., Segal J.B. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis of head-to-head randomized controlled trials. Depress. Anxiety. 2014;31:641–652. doi: 10.1002/da.22232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/da.22232</ArticleId>
            <ArticleId IdType="pubmed">24390912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yatham L.N., Liddle P.F., Sossi V., Erez J., Vafai N., Lam R.W., Blinder S. Positron emission tomography study of the effects of tryptophan depletion on brain serotonin(2) receptors in subjects recently remitted from major depression. Arch. Gen. Psychiatry. 2012;69:601–609. doi: 10.1001/archgenpsychiatry.2011.1493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.1493</ArticleId>
            <ArticleId IdType="pubmed">22664549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T., Connor T.J. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav. Immun. 2012;26:979–987. doi: 10.1016/j.bbi.2012.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2012.05.010</ArticleId>
            <ArticleId IdType="pubmed">22683764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prandovszky E., Gaskell E., Martin H., Dubey J.P., Webster J.P., McConkey G.A. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS ONE. 2011;6:e23866.  doi: 10.1371/journal.pone.0023866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0023866</ArticleId>
            <ArticleId IdType="pmc">PMC3177840</ArticleId>
            <ArticleId IdType="pubmed">21957440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares-Cunha C., Coimbra B., Sousa N., Rodrigues A.J. Reappraising striatal D1- and D2-neurons in reward and aversion. Neurosci. Biobehav. Rev. 2016;68:370–386. doi: 10.1016/j.neubiorev.2016.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2016.05.021</ArticleId>
            <ArticleId IdType="pubmed">27235078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. Ido and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry. 2005;10:538–544. doi: 10.1038/sj.mp.4001600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mp.4001600</ArticleId>
            <ArticleId IdType="pubmed">15494706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prendergast G.C., Malachowski W.J., Mondal A., Scherle P., Muller A.J. Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer. Int. Rev. Cell Mol. Biol. 2018;336:175–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6054468</ArticleId>
            <ArticleId IdType="pubmed">29413890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reus G.Z., Becker I.R.T., Scaini G., Petronilho F., Oses J.P., Kaddurah-Daouk R., Ceretta L.B., Zugno A.I., Dal-Pizzol F., Quevedo J., et al.  The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018;81:55–63. doi: 10.1016/j.pnpbp.2017.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2017.10.009</ArticleId>
            <ArticleId IdType="pubmed">29030243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fineberg N.A., Reghunandanan S., Simpson H.B., Phillips K.A., Richter M.A., Matthews K., Stein D.J., Sareen J., Brown A., Sookman D., et al.  Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res. 2015;227:114–125. doi: 10.1016/j.psychres.2014.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2014.12.003</ArticleId>
            <ArticleId IdType="pubmed">25681005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perlmutter S.J., Leitman S.F., Garvey M.A., Hamburger S., Feldman E., Leonard H.L., Swedo S.E. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153–1158. doi: 10.1016/S0140-6736(98)12297-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(98)12297-3</ArticleId>
            <ArticleId IdType="pubmed">10513708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooperstock M.S., Swedo S.E., Pasternack M.S., Murphy T.K., PANS/PANDAS Consortium  Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part III—Treatment and prevention of infections. J. Child Adolesc. Psychopharmacol. 2017;27:594–606. doi: 10.1089/cap.2016.0151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute of Mental Health (NIMH)  Information about PANS/PANDAS.  [(accessed on 30 March 2018)]; Available online:  https://www.nimh.nih.gov/labs-at-nimh/research-areas/clinics-and-labs/sbp/information-about-pans-pandas.shtml.</Citation>
        </Reference>
        <Reference>
          <Citation>Frankovich J., Swedo S., Murphy T., Dale R.C., Agalliu D., Williams K., Daines M., Hornig M., Chugani H., Sanger T., et al.  Clinical Management of pediatric acute-onset neuropsychiatric syndrome: Part II—Use of immunomodulatory therapies. J. Child Adolesc. Psychopharmacol. 2017;27:574–593. doi: 10.1089/cap.2016.0148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2016.0148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kellner M., Nowack S., Wortmann V., Yassouridis A., Wiedemann K. Does pregnenolone enhance exposure therapy in obsessive-compulsive disorder?—A pilot, interim report of a randomized, placebo-controlled, double-blind study. Pharmacopsychiatry. 2016;49:79–81. doi: 10.1055/s-0035-1569371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0035-1569371</ArticleId>
            <ArticleId IdType="pubmed">26797931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy T.K., Parker-Athill E.C., Lewin A.B., Storch E.A., Mutch P.J. Cefdinir for recent-onset pediatric neuropsychiatric disorders: A pilot randomized trial. J. Child Adolesc. Psychopharmacol. 2015;25:57–64. doi: 10.1089/cap.2014.0010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2014.0010</ArticleId>
            <ArticleId IdType="pmc">PMC4340343</ArticleId>
            <ArticleId IdType="pubmed">25299463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalueff A.V., Stewart A.M., Song C., Berridge K.C., Graybiel A.M., Fentress J.C. Neurobiology of rodent self-grooming and its value for translational neuroscience. Nat. Rev. Neurosci. 2016;17:45–59. doi: 10.1038/nrn.2015.8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn.2015.8</ArticleId>
            <ArticleId IdType="pmc">PMC4840777</ArticleId>
            <ArticleId IdType="pubmed">26675822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., Feliciano C., Chen M., Adams J.P., Luo J., et al.  Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007;448:894–900. doi: 10.1038/nature06104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06104</ArticleId>
            <ArticleId IdType="pmc">PMC2442572</ArticleId>
            <ArticleId IdType="pubmed">17713528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gehring W.J., Hiromi Y. Homeotic genes and the homeobox. Annu. Rev. Genet. 1986;20:147–173. doi: 10.1146/annurev.ge.20.120186.001051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.ge.20.120186.001051</ArticleId>
            <ArticleId IdType="pubmed">2880555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S.K., Tvrdik P., Peden E., Cho S., Wu S., Spangrude G., Capecchi M.R. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell. 2010;141:775–785. doi: 10.1016/j.cell.2010.03.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.03.055</ArticleId>
            <ArticleId IdType="pmc">PMC2894573</ArticleId>
            <ArticleId IdType="pubmed">20510925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimberg L., Benhar I., Mascaro-Blanco A., Alvarez K., Lotan D., Winter C., Klein J., Moses A.E., Somnier F.E., Leckman J.F., et al.  Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: A novel rat model of sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology. 2012;37:2076–2087. doi: 10.1038/npp.2012.56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2012.56</ArticleId>
            <ArticleId IdType="pmc">PMC3398718</ArticleId>
            <ArticleId IdType="pubmed">22534626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotan D., Cunningham M., Joel D. Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen. PLoS ONE. 2014;9:e101257.  doi: 10.1371/journal.pone.0101257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0101257</ArticleId>
            <ArticleId IdType="pmc">PMC4076315</ArticleId>
            <ArticleId IdType="pubmed">24979049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauls D.L., Raymond C.L., Stevenson J.M., Leckman J.F. A family study of gilles de la tourette syndrome. Am. J. Hum. Genet. 1991;48:154–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1682764</ArticleId>
            <ArticleId IdType="pubmed">1985456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eapen V., Pauls D.L., Robertson M.M. Evidence for autosomal dominant transmission in tourette’s syndrome. United kingdom cohort study. Br. J. Psychiatry. 1993;162:593–596. doi: 10.1192/bjp.162.5.593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.162.5.593</ArticleId>
            <ArticleId IdType="pubmed">8149109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kataoka Y., Kalanithi P.S., Grantz H., Schwartz M.L., Saper C., Leckman J.F., Vaccarino F.M. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with tourette syndrome. J. Comp. Neurol. 2010;518:277–291. doi: 10.1002/cne.22206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.22206</ArticleId>
            <ArticleId IdType="pmc">PMC2846837</ArticleId>
            <ArticleId IdType="pubmed">19941350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frick L.R., Williams K., Pittenger C. Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol. 2013;2013:608654. doi: 10.1155/2013/608654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/608654</ArticleId>
            <ArticleId IdType="pmc">PMC3652125</ArticleId>
            <ArticleId IdType="pubmed">23690824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morer A., Chae W., Henegariu O., Bothwell A.L., Leckman J.F., Kawikova I. Elevated expression of MCP-1, IL-2 and PTPR-N in basal ganglia of tourette syndrome cases. Brain Behav. Immun. 2010;24:1069–1073. doi: 10.1016/j.bbi.2010.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2010.02.007</ArticleId>
            <ArticleId IdType="pubmed">20193755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bilbo S.D., Schwarz J.M. The immune system and developmental programming of brain and behavior. Front. Neuroendocrinol. 2012;33:267–286. doi: 10.1016/j.yfrne.2012.08.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yfrne.2012.08.006</ArticleId>
            <ArticleId IdType="pmc">PMC3484177</ArticleId>
            <ArticleId IdType="pubmed">22982535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Attwells S., Setiawan E., Wilson A.A., Rusjan P.M., Mizrahi R., Miler L., Xu C., Richter M.A., Kahn A., Kish S.J., et al.  Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry. 2017;74:833–840. doi: 10.1001/jamapsychiatry.2017.1567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapsychiatry.2017.1567</ArticleId>
            <ArticleId IdType="pmc">PMC5710556</ArticleId>
            <ArticleId IdType="pubmed">28636705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott G., Zetterberg H., Jolly A., Cole J.H., De Simoni S., Jenkins P.O., Feeney C., Owen D.R., Lingford-Hughes A., Howes O., et al.  Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain. 2018;141:459–471. doi: 10.1093/brain/awx339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awx339</ArticleId>
            <ArticleId IdType="pmc">PMC5837493</ArticleId>
            <ArticleId IdType="pubmed">29272357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez T.V., Leckman J.F., Pittenger C. Genetic susceptibility in obsessive-compulsive disorder. Handb. Clin. Neurol. 2018;148:767–781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29478613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pishva E., Drukker M., Viechtbauer W., Decoster J., Collip D., van Winkel R., Wichers M., Jacobs N., Thiery E., Derom C., et al.  Epigenetic genes and emotional reactivity to daily life events: A multi-step gene-environment interaction study. PLoS ONE. 2014;9:e100935.  doi: 10.1371/journal.pone.0100935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0100935</ArticleId>
            <ArticleId IdType="pmc">PMC4072714</ArticleId>
            <ArticleId IdType="pubmed">24967710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlsson E., Frostell A., Ludvigsson J., Faresjo M. Psychological stress in children may alter the immune response. J. Immunol. 2014;192:2071–2081. doi: 10.4049/jimmunol.1301713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1301713</ArticleId>
            <ArticleId IdType="pubmed">24501202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leboyer M., Oliveira J., Tamouza R., Groc L. Is it time for immunopsychiatry in psychotic disorders? Psychopharmacology. 2016;233:1651–1660. doi: 10.1007/s00213-016-4266-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-016-4266-1</ArticleId>
            <ArticleId IdType="pubmed">26988846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leboyer M., Berk M., Yolken R.H., Tamouza R., Kupfer D., Groc L. Immuno-psychiatry: An agenda for clinical practice and innovative research. BMC Med. 2016;14:173.  doi: 10.1186/s12916-016-0712-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-016-0712-5</ArticleId>
            <ArticleId IdType="pmc">PMC5084344</ArticleId>
            <ArticleId IdType="pubmed">27788673</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
